

## OVERVIEW

**Net health benefit (NHB)** and **net monetary benefit (NMB)** are alternatives to using **incremental cost-effectiveness ratios (ICERs)** in the **economic evaluation of health technologies**.

Conventionally, **NHB** and **NMB** are regarded as **equivalent**, and the **cost-effectiveness threshold ( $\lambda$ )** is used to **weight** the components

of **NHB** when specifying **NMB**. We demonstrate **important differences** between these measures, and argue that **NMB is the preferred measure when making value-based reimbursement decisions**. We further show that using  $\lambda$  to **assign weights when specifying NMB is theoretically flawed**.

## METHODS

We consider the **circumstances** under which **NHB** and **NMB** have **non-equivalent implications** for interpreting economic evaluations.

We then consider the **appropriate weights** for specifying **NMB** within a **'social decision making' (SDM) perspective on social choice**.

## RESULTS

We demonstrate that **NHB and NMB are non-equivalent if  $\lambda$  changes over time or if  $\lambda$  is uncertain** (see panel to the right). Given this **non-equivalence**, **decision makers must decide which measure to use**.

**For value-based reimbursement decisions, NMB is preferred because it allows for differential weights to be assigned to health outcomes, while NHB does not.**

Under a **SDM perspective**, the weights that **ought to be assigned to health outcomes in different time periods** are determined by the **value that society currently places on health in each period**. **Since the value that society today places on health in future periods might differ from that implied by future values of  $\lambda$ , using  $\lambda$  to determine these weights is theoretically flawed.**

## CONCLUSIONS

Our findings have **important implications** for **value-based reimbursement decisions**.

The conventional **methods used for economic evaluation** assume that  $\lambda$  is a **stochastic parameter that does not vary over time**. Under this **restrictive assumption**, **NHB and NMB have equivalent implications**, so **either may be used to report the results of an economic evaluation**.

However, as our **theoretical and empirical understanding of  $\lambda$  improves**, it is increasingly clear that  $\lambda$  is **uncertain and unlikely to remain constant over time**.

**It is therefore important that we continue to develop the methods used for economic evaluation to account for any expected change and uncertainty in  $\lambda$ .**


After developing these updated methods, **NHB and NMB will have non-equivalent implications** for economic evaluations, so **decision makers will need to decide which to use in their evaluations**.

**Using NHB is inappropriate, since differential weights cannot be assigned to health outcomes to which the decision maker attaches differential value**.

**Conventional estimates of NMB are also inappropriate under a SDM perspective, since future values of  $\lambda$  may not reflect the value that society today assigns to future health outcomes**.

**It is time to move on from using NHB and adopt a measure of NMB that appropriately reflects society's valuation of health.**

## THE NON-EQUIVALENCE OF 'NET HEALTH BENEFIT' AND 'NET MONETARY BENEFIT'



An **intervention** is compared to a **comparator** over a **two-year horizon**.

In year 1, the **intervention** costs \$1.8m and provides 36 QALYs, the **comparator** costs \$0.6m and provides 44 QALYs, and  $\lambda$  is \$50,000 per QALY.

In year 2, the **intervention** costs \$0.6m and provides 60 QALYs, the **comparator** costs \$1.2m and provides 40 QALYs, and  $\lambda$  either **remains constant** (at \$50,000 per QALY), **decreases** (to \$40,000 per QALY), or **increases** (to \$60,000 per QALY).

In year 1,  $\lambda$  is \$50,000 per QALY, so the \$1.8m cost of the **intervention** displaces 36 QALYs. Within year 1 **only**, the **NHB** of the **intervention** is therefore  $36 - 36 = 0$  QALYs, so its **NMB** is  $0 \times \$50,000$  per QALY = \$0m. Meanwhile, in year 1, the \$0.6m cost of the **comparator** displaces 12 QALYs, so its **NHB** in year 1 **only** is  $44 - 12 = 32$  QALYs and its **NMB** is  $32 \times \$50,000$  per QALY = \$1.6m.

If  $\lambda$  **remains at \$50,000 per QALY** in year 2, the **intervention** (\$0.6m) displaces 12 QALYs, so its **NHB** in year 2 **only** is  $60 - 12 = 48$  QALYs, and its **NMB** is  $48 \times \$50,000 = \$2.4m$ .

The **intervention's** total **NHB** over both years is  $0 + 48 = 48$  QALYs, and its total **NMB** is  $\$0m + \$2.4m = \$2.4m$ . Meanwhile, the **comparator** (\$1.2m) displaces 24 QALYs, so its **NHB** in year 2 **only** is  $40 - 24 = 16$  QALYs and its **NMB** is  $16 \times \$50,000 = \$0.8m$ .

The **comparator's** total **NHB** over both years is  $32 + 16 = 48$  QALYs, while its total **NMB** over both years is  $\$1.6m + \$0.8m = \$2.4m$ .

**If  $\lambda$  remains constant in year 2, the intervention and comparator are equally cost-effective using either NHB (48 QALYs each) or NMB (\$2.4m each), so NHB and NMB have equivalent implications for economic evaluations.**

If  $\lambda$  **decreases to \$40,000 per QALY** in year 2, the **intervention** (\$0.6m) displaces 15 QALYs, so its **NHB** in year 2 **only** is  $60 - 15 = 45$  QALYs and its **NMB** (using  $\lambda$  as the weight) is  $45 \times \$40,000 = \$1.8m$ .

The **intervention's** total **NHB** over both years is  $0 + 45 = 45$  QALYs, and its total **NMB** is  $\$0m + \$1.8m = \$1.8m$ . Meanwhile, the **comparator** (\$1.2m) displaces 30 QALYs, so its **NHB** in year 2 **only** is  $40 - 30 = 10$  QALYs and its **NMB** is  $10 \times \$40,000 = \$0.4m$ .

The **comparator's** total **NHB** over both years is  $32 + 10 = 42$  QALYs, while its total **NMB** over both years is  $\$1.6m + \$0.4m = \$2.0m$ .

**If  $\lambda$  decreases to \$40,000 per QALY in year 2, using NHB favours the intervention (45 > 42 QALYs), while using NMB favours the comparator (\$2.0m > \$1.8m). NHB and NMB have non-equivalent implications for economic evaluations.**

If  $\lambda$  **increases to \$60,000 per QALY** in year 2, the **intervention** (\$0.6m) displaces 10 QALYs, so its **NHB** in year 2 **only** is  $60 - 10 = 50$  QALYs and its **NMB** is  $50 \times \$60,000 = \$3.0m$ .

The **intervention's** total **NHB** over both years is  $0 + 50 = 50$  QALYs, while its total **NMB** over both years is  $\$0m + \$3.0m = \$3.0m$ . Meanwhile, the **comparator** (\$1.2m) displaces 20 QALYs, so its **NHB** in year 2 **only** is  $40 - 20 = 20$  QALYs and its **NMB** is  $20 \times \$60,000 = \$1.2m$ .

The **comparator's** total **NHB** over both years is  $32 + 20 = 52$  QALYs, while its total **NMB** over both years is  $\$1.6m + \$1.2m = \$2.8m$ .

**If  $\lambda$  increases to \$60,000 per QALY in year 2, using NHB favours the comparator (52 > 50 QALYs), while using NMB favours the intervention (\$3.0m > \$2.8m). NHB and NMB have non-equivalent implications for economic evaluations.**